HLS Therapeutics Appoints Christine Elliott to Board of Directors

The latest update is out from HLS Therapeutics Inc ( (TSE:HLS) ).

HLS Therapeutics Inc. has announced the appointment of Christine Elliott to its Board of Directors. With her extensive experience as Ontario’s Deputy Premier and Minister of Health, Elliott brings valuable insights into the Canadian healthcare landscape, particularly in regulatory and reimbursement frameworks. Her appointment is expected to aid HLS in expanding access to therapies and introducing new medicines, thereby benefiting patients and healthcare providers across Canada.

More about HLS Therapeutics Inc

HLS Therapeutics Inc. is a pharmaceutical company formed in 2015, focused on the acquisition and commercialization of late-stage development, commercial stage promoted, and established branded pharmaceutical products in North America. The company primarily addresses unmet needs in the treatment of psychiatric disorders and cardiovascular disease, leveraging a management team with a strong track record in these therapeutic areas.

YTD Price Performance: 0.25%

Average Trading Volume: 28,096

Technical Sentiment Consensus Rating: Hold

Current Market Cap: C$124.6M

For an in-depth examination of HLS stock, go to TipRanks’ Stock Analysis page.